53 related articles for article (PubMed ID: 24139873)
1. Sorafenib tosylate as a radiosensitizer in malignant astrocytoma.
Sherman JH; Kirzner J; Siu A; Amos S; Hussaini IM
J Clin Neurosci; 2014 Jan; 21(1):131-6. PubMed ID: 24139873
[TBL] [Abstract][Full Text] [Related]
2. Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Dai XF; Ding J; Zhang RG; Ren JH; Ma CM; Wu G
Int J Radiat Biol; 2013 Sep; 89(9):724-31. PubMed ID: 23682582
[TBL] [Abstract][Full Text] [Related]
3. The mechanisms responsible for the radiosensitizing effects of sorafenib on colon cancer cells.
Kim EH; Kim MS; Jung WG
Oncol Rep; 2014 Dec; 32(6):2421-8. PubMed ID: 25242034
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib acts synergistically in combination with radiotherapy without causing intestinal damage in colorectal cancer.
Jeong YK; Kim MS; Lee JY; Kim EH; Kim W; Ha H; Jeong JH
Tumori; 2013; 99(2):176-82. PubMed ID: 23748811
[TBL] [Abstract][Full Text] [Related]
5. Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
Yun SM; Jung KH; Lee H; Son MK; Seo JH; Yan HH; Park BH; Hong S; Hong SS
Cancer Lett; 2013 May; 331(2):250-61. PubMed ID: 23340175
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.
Heravi M; Tomic N; Liang L; Devic S; Holmes J; Deblois F; Radzioch D; Muanza T
Anticancer Drugs; 2012 Jun; 23(5):525-33. PubMed ID: 22357220
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo.
Yu W; Gu K; Yu Z; Yuan D; He M; Ma N; Lai S; Zhao J; Ren Z; Zhang X; Shao C; Jiang GL
Cancer Lett; 2013 Feb; 329(1):109-17. PubMed ID: 23142289
[TBL] [Abstract][Full Text] [Related]
8. RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.
Shi JH; Liu SZ; Wierød L; Scholz H; Anmarkrud JA; Huitfeldt HS; Zhang SJ; Line PD
J Surg Oncol; 2013 Mar; 107(4):393-401. PubMed ID: 22927239
[TBL] [Abstract][Full Text] [Related]
9. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
10. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C
Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
Xiao RZ; He CM; Xiong MJ; Ruan XX; Wang LL; Chen Y; Lin DJ
Oncol Rep; 2013 May; 29(5):1895-901. PubMed ID: 23467984
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts.
Lin JC; Huang WP; Liu CL; Lee JJ; Liu TP; Ko WC; Huang YC; Hsu ML; Wu CH; Chen YJ
Transplantation; 2013 Mar; 95(6):791-800. PubMed ID: 23354299
[TBL] [Abstract][Full Text] [Related]
13. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
[TBL] [Abstract][Full Text] [Related]
14. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
15. The kinase inhibitor Sorafenib impairs the antiviral effect of interferon α on hepatitis C virus replication.
Himmelsbach K; Hildt E
Eur J Cell Biol; 2013 Jan; 92(1):12-20. PubMed ID: 23107224
[TBL] [Abstract][Full Text] [Related]
16. Human glioblastoma and carcinoma xenograft tumors treated by combined radiation and imatinib (Gleevec).
Oertel S; Krempien R; Lindel K; Zabel A; Milker-Zabel S; Bischof M; Lipson KE; Peschke P; Debus J; Abdollahi A; Huber PE
Strahlenther Onkol; 2006 Jul; 182(7):400-7. PubMed ID: 16826359
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
18. Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Fumarola C; Caffarra C; La Monica S; Galetti M; Alfieri RR; Cavazzoni A; Galvani E; Generali D; Petronini PG; Bonelli MA
Breast Cancer Res Treat; 2013 Aug; 141(1):67-78. PubMed ID: 23963659
[TBL] [Abstract][Full Text] [Related]
19. Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Honma Y; Harada M
Exp Cell Res; 2013 Aug; 319(14):2166-78. PubMed ID: 23727131
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo.
Kuo YC; Lin WC; Chiang IT; Chang YF; Chen CW; Su SH; Chen CL; Hwang JJ
Biomed Pharmacother; 2012 Feb; 66(1):12-20. PubMed ID: 22265104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
